Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

Table 3 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort, n (%)

Dependent: Survival (OS/30, status OS)		All patients	HR (univariable)	HR (multivariable)
Gender	Male	87 (64.0)	-	-
	Female	49 (36.0)	0.83 (0.45-1.50, P = 0.531)	1.02 (0.56-1.91, P = 0.928)
Age	> 60	60 (44.1)	-	-
	≤ 60	76 (55.9)	1.20 (0.67-2.14, P = 0.540)	1.00 (0.56-1.80, P = 0.995)
ECOG	1	125 (91.9)	-	-
	2	11 (8.1)	1.14 (0.41-3.19, P = 0.803)	-
Number of metastatic organs	1	80 (58.8)	-	-
	≥ 2	56 (41.2)	1.50 (0.85-2.64, P = 0.163)	-
Primary tumor location	Right colon	51 (37.5)	-	-
	Left colon and rectum	85 (62.5)	1.15 (0.64-2.07, P = 0.631)	-
Liver metastasis	No	53 (39.0)	-	-
	Yes	83 (61.0)	3.34 (1.73-6.46, P < 0.001)	3.36 (1.71-6.60, P < 0.001)
Lung metastasis	No	94 (69.1)	-	-
	Yes	42 (30.9)	0.65 (0.34-1.24, P = 0.192)	-
RAS	Unknown	26 (19.1)	-	-
	Wild type	24 (17.6)	1.00 (0.41-2.43, P = 0.993)	-
	Mutation	86 (63.2)	0.89 (0.42-1.90, P = 0.767)	-
Group	Control group	108 (79.4)	-	-
	Experimental group	28 (20.6)	0.80 (0.34-1.89, P = 0.607)	0.80 (0.34-1.91, P = 0.620)

OS: Overall survival; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group.